Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 15, 2019

SELL
$1.44 - $3.29 $33,076 - $75,571
-22,970 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$1.74 - $4.66 $39,967 - $107,040
22,970 New
22,970 $59,000

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $661M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Paloma Partners Management CO Portfolio

Follow Paloma Partners Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Paloma Partners Management CO with notifications on news.